| Literature DB >> 34696703 |
Hongwei Zheng1, Wenlun Wang1, Shichang Li1, Lin Han1.
Abstract
Cholesteatoma of the middle ear is a kind of cystic disease with clear boundary formed by the abnormal growth of keratosquamous epithelium in temporal bone. Cholesteatoma otitis caused by it is a common disease in otorhinolaryngology. The EPR effect promotes the selective distribution of macromolecular substances in tumor tissues, which can increase drug efficacy. The purpose of this paper is to prepare and deliver the mir34a small molecule regulator, rubine, by nanotechnology, and to deliver it to the cells successfully. It can passively target tumor tissue through EPR effect, and play its regulatory role on miR-34a, thus inhibiting the growth of cholesteatoma cells. The effects of nano delivery on apoptosis and PIEN/P13K/AKt of children with middle ear choledochoma were tested in this paper. The experimental results were conducted on cholesteatoma cells as cell lines and balb/c nude mice as experimental objects. The expression of PTEN/PI3K/AKT in experimental group and control group was detected by immunohistochemistry. Apoptosis was discussed by cell activity detection. The physical and chemical properties, encapsulation efficiency, drug release ability in vitro and antitumor activity of nanoparticles in vitro and in vivo were studied. The results of cell level experiments in vitro showed that free RUBINE caused about 15% apoptosis, which was not different from RC NPs. The results showed that the nanoparticles could improve the expression of miR-34 in the cells, and then regulate the expression of Bcl-2, Cdk6 and CyclinD1, and play the inhibitory effect of miR-34a on the proliferation and migration of tumor cells.Entities:
Keywords: NANO delivery vector; PTEN/PI3K/AKT; apoptosis; cholesteatoma in middle ear of children
Mesh:
Substances:
Year: 2021 PMID: 34696703 PMCID: PMC8806951 DOI: 10.1080/21655979.2021.1984718
Source DB: PubMed Journal: Bioengineered ISSN: 2165-5979 Impact factor: 3.269
Figure 1.Cell viability at different RUBONE concentrations
Figure 2.Apoptosis of cells treated with different components
Figure 3.MiR-34a expression level
Expression levels of Bcl-2, Cdk6 and CyclinD1 mRNA
| Bcl-2 | CDK6 | CyclinD1mRNA | |
|---|---|---|---|
| CTR | 0.98 | 0.98 | 0.98 |
| BC-NPs | 0.96 | 0.99 | 0.97 |
| Free RUBONE | 0.095 | 0.29 | 0.31 |
| RC-NPs | 0.12 | 0.46 | 0.58 |
Figure 4.The volumes of tumors
Figure 5.Expression levels of miR-34a, Bcl-2, CyclinD1 and Cdk6 in tumor tissues
Expression of p-AKT in CHOLESTEATOMA cells of middle ear in children
| Group | N | p-AKT | Positive rate | | ||||
|---|---|---|---|---|---|---|---|---|
| - | + | ++ | +++ | %/ | p | |||
| Experience group | 52 | 9 | 18 | 16 | 9 | 82.69 | 22.11 | |
| Control group | 20 | 15 | 4 | 1 | 0 | 22.12 | ||
Expression of PTEN in middle ear CHOLESTEATOMA
| Group | N | PTEN | Positive rate | | ||||
|---|---|---|---|---|---|---|---|---|
| - | + | ++ | +++ | % | p | |||
| Experience group | 52 | 32 | 11 | 7 | 2 | 39.21 | 12.06 | |
| Control group | 20 | 3 | 7 | 6 | 4 | 85.12 | ||
|
|
|
| Bcl-2 | B-cell lymphoma-2 |
| EGFR | epidermal growth factor receptor |
| NSCLC | nonsmall-cell lung cancer |